Purna Pharmaceuticals NV
https://www.purna.be/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Purna Pharmaceuticals NV
Hyloris Raises €15m In Private Equity Offering
Value-added medicines firm Hyloris has raised €15m from new and existing investors through a private equity offering of nearly one million new shares.
Hyloris Outlines Ambitious Growth Strategy During Full-Year Results
Hyloris expects to expand its portfolio to around 30 candidates by 2024, bolstered by €50m in cash and cash equivalents as of the end of 2021.
Hyloris And Purna Strike Value-Added Development Deal
Value-added medicines specialist Hyloris has struck a deal worth up to €4.3m with Purna Female Healthcare to develop a treatment for vulvovaginal candidiasis that combines miconazole and domiphen bromide.
Company Information
- Industry
- Biotechnology
- Contract Manufacturing Organization
-
Pharmaceuticals
- OTC, Consumer
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice